Trubion Pharmaceuticals Inc. (TRBN)

[surf1944]

4:01PM Trubion Pharma announces Pfizer to continue development of SBI-087 and discontinue development of TRU-015 (TRBN) 3.66 -0.05 : Co announces announced Pfizer's (PFE) decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.